

Emergence of multiple SARS-CoV-2 antibody escape variants in an immunocompromised host undergoing convalescent plasma treatment

3

4 Liang Chen¹, Michael C Zody², Jose R Mediavilla¹, Marcus H Cunningham¹, Kaelea Composto¹,
5 Kar Fai Chow³, Milena Kordalewska¹, André Corvelo², Dayna M Oschwald², Samantha
6 Fennessey², Marygrace Zetkulic², Sophia Dar³, Yael Kramer³, Barun Mathema³, Tom Maniatis²,
7 David S Perlin¹, Barry N Kreiswirth¹

8

1. Hackensack Meridian Health Center for Discovery and Innovation, Nutley, NJ, USA
 2. New York Genome Center, New York, NY, USA
 3. Hackensack Medical University Center, Hackensack, NJ, USA.
 4. Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY, USA

14

15

16

17 Corresponding author: Dr. Barry N Kreiswirth, Barry.Kreiswirth@hmh-cdi.org

18

19

20 **Abstract**

21 SARS-CoV-2 Variants of Concerns (VOC), e.g., B.1.351 (20H/501Y.V2) and P1 (20J/501Y.V3),
22 harboring N-terminal domain (NTD) or the receptor-binding domain (RBD) (e.g., E484K)
23 mutations, exhibit reduced in vitro susceptibility to convalescent serum, commercial antibody
24 cocktails, and vaccine neutralization, and have been associated with reinfection. The
25 accumulation of these mutations could be the consequence of intra-host viral evolution due to
26 prolonged infection in immunocompromised hosts. In this study, we document the
27 microevolution of SARS-CoV-2 recovered from sequential tracheal aspirates from an
28 immunosuppressed patient on tacrolimus, steroids and convalescent plasma therapy, and
29 identify the emergence of multiple NTD and RBD mutations associated with reduced antibody
30 neutralization as early as three weeks after infection. SARS-CoV-2 genomes from the first
31 swab (Day 0) and three tracheal aspirates (Day 7, 21 and 27) were compared at the sequence
32 level. We identified five different S protein mutations at the NTD or RBD regions from the
33 second tracheal aspirate sample (21 Day). The S:Q493R substitution and S:243-244LA deletion
34 had ~70% frequency, while ORF1a:A138T, S:141-144LGVY deletion, S:E484K and S:Q493K
35 substitutions demonstrated ~30%, ~30%, ~20% and ~10% mutation frequency, respectively.
36 However, the third tracheal aspirate sample collected one week later (Day 27) was
37 predominated by the haplotype of ORF1a:A138T, S:141-144LGVY deletion and S:E484K (>
38 95% mutation frequency). Notably, S protein deletions (141-144LGVY and 243-244LA deletions
39 in NTD region) and substitutions (Q493K/R and E484K in the RBD region) previously showed
40 reduced susceptibility to monoclonal antibody or convalescent plasma. The observation supports
41 the hypothesis that VOCs can independently arise and that immunocompromised patients on
42 convalescent plasma therapy are potential breeding grounds for immune-escape mutants.

43

44 **Competing Interest Statement**

45 The authors have declared no competing interest.

46

47 **Funding Statement**

48 The study was in part supported by Center for Discovery and Innovation and Hackensack

49 Meridian Health Foundation.

50

51

52 **Introduction**

53 After a year of the COVID-19 pandemic, with over 100 million global cases and 2.80 million
54 deaths, the world is now focused on the biological consequences of the distribution of vaccines
55 and the spread of “Variants of Concerns” (VOC). Three SAR-CoV-2 VOCs, i.e., B.1.1.7
56 (20I/501Y.V1), B.1.351 (20H/501Y.V2) and P1 (20J/501Y.V3) carrying the spike protein N501Y
57 mutation emerged in the UK, South Africa, Brazil and Japan¹, and have been associated with
58 high transmissibility due to the increased affinity to the ACE receptor. In each of these viruses,
59 the spike protein contains clustered mutations in the N-terminal domain (NTD) and the receptor-
60 binding domain (RBD) (e.g., E484K) regions. Some VOCs carrying these mutations show
61 reduced *in vitro* susceptibility to convalescent serum, commercial antibody cocktails, and
62 vaccine neutralization, and have been associated with reinfection^{2,3}. The accumulation of these
63 mutations is assumed to be the consequence of intra-host viral evolution due to prolonged
64 infection in immunocompromised hosts^{4,5}. A recent NEJM report from Choi et al.⁴ described the
65 emergence of antibody escape mutations from an immunocompromised patient 75 days after
66 infection. Here, we document the microevolution of SARS-CoV-2 recovered from sequential
67 tracheal aspirates from an immunosuppressed patient on tacrolimus, steroids and convalescent
68 plasma therapy, and identify the emergence of multiple NTD and RBD mutations associated
69 with reduced antibody neutralization as early as three weeks after infection.

70

71 **Materials and Methods**

72 **SARS-CoV-2 detection**

73 Total nucleic acid (TNA) from nasopharyngeal swabs was extracted by the MagNAPure 24
74 system (Roche Life Science) and Viral RNA from tracheal aspirates was extracted using
75 QIAamp Viral RNA Mini Kit (Qiagen), following the manufacturer's instructions. SARS-CoV-2

76 detection was performed using the CDI-enhanced COVID-19 test⁶, targeting SARS-CoV-2 E and
77 N2 genes. The test was approved for use on March 12, 2020 under FDA Emergency Use
78 Authorization for COVID-19 and has a limit of detection less than 20 viral genome copies per
79 reaction. A specimen is considered positive if the gene target has a cycle threshold (Ct) value <
80 40.

81

82 **SARS-CoV-2 viral sequencing and genomic analysis**

83 SARS-CoV-2 targeted assay libraries were prepared using the AmpliSeq Library Plus and cDNA
84 Synthesis for Illumina kits (Illumina) in accordance with manufacturer's recommendations.
85 Briefly, 20ng of RNA was reverse transcribed followed by amplification of cDNA targets using
86 the Illumina SARS-CoV-2 research panel (Illumina). The amplicons were then partially digested,
87 ligated to AmpliSeq CD Indexes, and then amplified using 18 cycles of PCR. Libraries were
88 quantified using fluorescent-based assays including PicoGreen (Life Technologies), Qubit
89 Fluorometer (Invitrogen), and Fragment Analyzer (Advanced Analytics). Final libraries were
90 sequenced on a NovaSeq 6000 sequencer (v1 chemistry) with 2x150bp.

91

92 Short read-data were filtered and processed prior to alignment. Read pairs that did not contain a
93 single 19bp seed k-mer in common with the SARS-CoV-2 genome reference (NC_045512.2)
94 were discarded. Adapter sequences and low quality (Q < 20) bases were trimmed from the
95 remaining reads, using Cutadapt v2.10¹⁷. Processed reads were then mapped to the SARS-
96 CoV-2 genome reference using BWA-MEM v0.7.17²⁸ and only read pairs with at least one
97 alignment spanning a minimum of 42 bp in the reference and starting before position 29,862 (to
98 exclude polyadenine-only alignments) were kept. Genome sequences were determined by
99 alignment pileup consensus calling with a minimum support of 5 reads using Samtools v1.11

100 and bcftools v1.11⁹. SNP and InDels were called using FreeBayes v1.3.5
101 (<https://github.com/freebayes>), followed by annotation using SnpEff v4.5¹⁰. A minimum variant
102 calling frequency was set to be 5% to identify within host variations.

103

104 The resulting SARS-CoV-2 viral genome sequences were uploaded to Nextclade server
105 (<https://clades.nextstrain.org/>) to assign Nextstrain clades¹¹. SARS-CoV-2 lineage was
106 determined using Pangolin v2.3.0 (<https://github.com/cov-lineages/pangolin>) and GISAID clade
107 is determined based upon the clade specific marker variants from <https://www.gisaid.org>¹². In
108 addition, 2,282 SARS-CoV-2 genomes with E484K mutation were downloaded from GISAID
109 database¹² (date as 2/12/2021), and the genomes with less than 1% ambiguous nucleotides
110 (Ns) and > 28,900 bp were aligned using MAFFT v7.475¹² using default setting. A maximum
111 likelihood phylogenetic tree was constructed using IQ-TREE v2.1.2¹³ with automatic model
112 selection and 1000-bootstrap replicates. The resulting tree was annotated using iTOL v5¹⁴.

113

114 **Informed consent**

115 Informed consent was obtained from this patient and the study was approved by Hackensack
116 Meridian Health Institutional Review Board (IRB) under protocol Pro2018-1022.

117

118 **Results**

119 **Case description**

120 A male in early 50s presented to a Northern Jersey hospital with fever, productive cough,
121 generalized myalgias, and progressive shortness of breath for 4 days (**Fig1A**). He had history of
122 deceased donor kidney transplant for end-stage renal disease (ESRD) secondary to HTN,

123 complicated by cellular graft rejection and recurrent collapsing focal segmental
124 glomerulosclerosis. On physical examination, the patient had fever of temperature 102.3F, O₂
125 Saturation 90% on 100% non-rebreather. His examination was significant for tachypnea, but
126 otherwise unremarkable. He was admitted under the suspicion of COVID-19 pneumonia. His
127 medications were significant for his immunosuppressive regime of mycophenolic acid,
128 prednisone, and tacrolimus along with multiple anti-hypertensive medications.

129

130 COVID-19 was confirmed to be positive by RT-PCR (Day 0). Chest X-Ray (CXR) revealed
131 dense infiltrates bilaterally reflective of his viral pneumonia. Given his multiple comorbidities,
132 immunosuppressed status, and work of breathing, he was admitted to the ICU for high flow and
133 awake proning and was started on broad spectrum meropenem treatment. His anti-
134 hypertensives were discontinued due to his normotension, and his immunosuppressive regime
135 was continued except for mycophenolate given the likelihood of serious infection.

136

137 He was treated with high-titer convalescent plasma (Day 1) and tocilizumab (Day 2). Due to his
138 worsening respiratory status, the patient was intubated (Day 2). Antibiotics were switched to
139 vancomycin and piperacillin-tazobactam and then discontinued as the patient was afebrile (Day
140 3). The patient was found to have bilateral deep venous thrombosis and was started on
141 therapeutic heparin (Day 3). Due to worsening hypoxic respiratory failure despite complete
142 support from mechanical ventilation, the patient was subsequently cannulated and placed on
143 veno-venous extra-corporeal oxygenation (ECMO) (Day 5). He went into rapid atrial flutter as
144 well and was started on intravenous amiodarone (Day 5). His renal failure attributed to multiple
145 factors such as his tacrolimus, COVID-19 injury, and hypotension slowly began to improve.
146 Oxygenation began to improve and stabilize, leading to tracheostomy (Day 16) and ECMO

147 explantation (Day 20). The patient, however, became febrile and septic with *Enterococcus*
148 bacteremia and *Proteus mirabilis* pneumonia and was restarted on vancomycin and piperacillin-
149 tazobactam (Day 20). He subsequently developed septic shock and was started on
150 vasopressors (Day 21). Following the antibiogram, antibiotics were de-escalated to ampicillin
151 (Day 21) and continued for a 7-day course. The septic shock resolved, and the patient was re-
152 started on his anti-hypertensives once his blood pressure began to remain stable. His course
153 continued to be complicated by periodic desaturations and wide and narrow complex
154 tachycardia, anemia, and thrombocytopenia. He slowly improved permitting ventilation and
155 sedation weaning. As his dysphagia was unresolved during his recovery, percutaneous
156 endoscopic gastrostomy (PEG) tube was placed (Day 28) to improve nutritional status. He was
157 transferred to the step-down unit as he continued to recover (Day 49) and was discharged to a
158 long-term care facility (Day 64) requiring ventilatory support only at night. Unexpectedly, the
159 patient expired presumably due to hypoxic respiratory failure secondary to his COVID-19
160 pneumonia (Day 94).

161

162 **Genomic analysis**

163 SARS-CoV-2 positive qRT-PCR results (**Table 1**) were obtained from three nasopharyngeal
164 swab samples (on Day 0, 34 and 41) and three tracheal aspirates (on Day 7, 21 and 27); the
165 first swab and the three tracheal aspirates were available for viral genome sequencing (**Fig1A**).
166 The genotype of the initial swab and tracheal aspirate (Day 7) were identical. The genomes of
167 these two samples harbored 14 mutations (versus Wuhan-Hu-1), and were assigned as
168 Nextstrain clade 20C, Pangolin lineage B.1.369 and GISAID clade GH, distinct from the three
169 501Y VOCs (**Fig1B, C**). The second tracheal aspirate specimen (from Day 21) showed five
170 different S protein mutations at the NTD or RBD regions. The S protein Q493R substitution and
171 243-244LA deletion had ~70% frequency, while ORF1a A138T, S protein 141-144LGVY

172 deletion, E484K and Q493K substitutions demonstrated ~30%, ~30%, ~20% and ~10%
173 mutation frequency, respectively (**Fig1D**). However, the third tracheal aspirate sample collected
174 one week later (Day 27) was predominated by the haplotype of ORF1a:A138T, S:141-144LGVY
175 deletion and S:E484K (> 95% mutation frequency) (**Fig1D**).

176

177 The 141-144LGVY and 243-244LA deletions are located in the recently described “Recurrent
178 Deletion Region” (RDR) 2 and 4¹⁵, respectively, within the NTD of the spike protein. The
179 appearance of deletions in the RDR region of the spike protein has been observed during
180 prolonged infections in immunocompromised patients and proposed as a mechanism that
181 evades the proofreading activity of the virus and accelerates adaptive evolution. The 141-
182 144LGVY and 243-244LA deletions confer resistance to NTD specific monoclonal antibody in
183 neutralization assays¹⁵. The Q493K/R and E484K substitutions are located in the RBD region
184 of the spike protein, and associated with resistance to monoclonal antibodies or convalescent
185 plasma^{16,17}. In particular, the E484K mutation has been linked to the rapid spread of B.1.351
186 and B.1.1.28 variants in South Africa and Brazil, respectively. To date, over 17,000 E484K
187 variants have been identified from >60 countries within various SARS-CoV2 lineages
188 (www.gisaid.org) (**Fig2**), potentially posing significant challenges to vaccine efficacy and
189 increased reinfection risk. Intriguingly, the co-occurrence of 141-144LGVY and E484K in the
190 third tracheal aspirate specimen completely replaced other mutants, suggesting this haplotype
191 may have compensated for a fitness cost or have higher antibody resistance level.

192

193 **Discussion**

194 While most immunocompetent hosts are able to achieve resolution of COVID-19 within 1-3
195 weeks after symptoms, there is emerging evidence that a pre-existing immunocompromised
196 state is associated with prolonged infection and significantly increased risk of severe

197 disease^{4,5,18,19}. Although the immunological mechanisms for control of SARS-CoV-2 in humans
198 have not been clearly elucidated, it is likely that both cytotoxic T-cells and antibody-mediated
199 immune responses are important for clearance of the viral infection^{18,20}. Activation of type I and
200 type III interferons has been postulated to be a key contributor to innate immune control^{20,21}, in
201 addition to CD8⁺ effector T-cell–mediated killing of virally infected cells and CD4⁺ T cell–
202 dependent enhancement of CD8⁺ and B-cell responses^{18,20}. Following viral clearance, long-
203 term memory T-cells are formed for prolonged antiviral immunity. Chronic viral infection must
204 evade or suppress some part of this pathway. Moreover, animal studies have shown that
205 chronic viral infections were characterized by persistent antigenic activation of T-cells, ultimately
206 driving a nonresponsive cell state known as T-cell “exhaustion”. This state was often
207 accompanied by lymphopenia²⁰. This patient’s anti-rejection regimen of mycophenolate and
208 tacrolimus targets and inhibits T-cell function and replication, and treatment with prednisone
209 may compromise the ‘proliferative burst’ of effector T-cells²². While mycophenolate was
210 discontinued, the patient was maintained on tacrolimus and prednisone during his entire
211 hospitalization, which likely further impaired his cellular immunity against SARS-CoV-2. In our
212 case, the treatment with convalescent plasma in combination with the routine maintenance of an
213 anti-rejection regiment may have facilitated a “breeding ground” and the emergence of immune-
214 escape mutants. Although we have no evidence that these two escape variants were
215 transmitted, this case suggest that VOCs may arise among immunocompromised populations
216 undergoing anti-SARS-CoV-2 therapy, and enhanced measures will be required to reduce
217 transmission.

218

219 **Acknowledgement**

220 We gratefully acknowledge the Authors from the Originating laboratories responsible for
221 obtaining the specimens and the Submitting laboratories where genetic sequence data were
222 generated and shared via the GISAID Initiative, on which this research is based.

223

224 **Reference**

- 225 1. Galloway SE, Paul P, MacCannell DR, et al. Emergence of SARS-CoV-2 B.1.1.7
226 Lineage - United States, December 29, 2020-January 12, 2021. MMWR Morb Mortal Wkly Rep
227 2021;70:95-9.
- 228 2. Wang Z, Schmidt F, Weisblum Y, et al. mRNA vaccine-elicited antibodies to SARS-CoV-
229 2 and circulating variants. bioRxiv 2021:2021.01.15.426911.
- 230 3. Greaney AJ, Loes AN, Crawford KHD, et al. Comprehensive mapping of mutations to
231 the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum
232 antibodies. bioRxiv 2021:2020.12.31.425021.
- 233 4. Choi B, Choudhary MC, Regan J, et al. Persistence and Evolution of SARS-CoV-2 in an
234 Immunocompromised Host. N Engl J Med 2020;383:2291-3.
- 235 5. Avanzato VA, Matson MJ, Seifert SN, et al. Case Study: Prolonged Infectious SARS-
236 CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell
237 2020;183:1901-12.e9.
- 238 6. Lombardi L, Turner SA, Zhao F, Butler G. Gene editing in clinical isolates of Candida
239 parapsilosis using CRISPR/Cas9. Scientific reports 2017;7:8051.
- 240 7. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing
241 reads. EMBnetjournal 2011;17:10-2.
- 242 8. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform.
243 Bioinformatics 2009;25:1754-60.

- 244 9. Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/Map format and
245 SAMtools. Bioinformatics 2009;25:2078-9.
- 246 10. Cingolani P, Platts A, Wang le L, et al. A program for annotating and predicting the
247 effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila
248 melanogaster strain w1118; iso-2; iso-3. Fly 2012;6:80-92.
- 249 11. Hadfield J, Megill C, Bell SM, et al. Nextstrain: real-time tracking of pathogen evolution.
250 Bioinformatics 2018;34:4121-3.
- 251 12. Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID's innovative
252 contribution to global health. Glob Chall 2017;1:33-46.
- 253 13. Nguyen LT, Schmidt HA, von Haeseler A, Minh BQ. IQ-TREE: a fast and effective
254 stochastic algorithm for estimating maximum-likelihood phylogenies. Mol Biol Evol 2015;32:268-
255 74.
- 256 14. Letunic I, Bork P. Interactive Tree Of Life (iTOL) v4: recent updates and new
257 developments. Nucleic Acids Res 2019;47:W256-w9.
- 258 15. McCarthy KR, Rennick LJ, Nambulli S, et al. Recurrent deletions in the SARS-CoV-2
259 spike glycoprotein drive antibody escape. Science 2021:eabf6950.
- 260 16. Weisblum Y, Schmidt F, Zhang F, et al. Escape from neutralizing antibodies by SARS-
261 CoV-2 spike protein variants. eLife 2020;9.
- 262 17. Starr TN, Greaney AJ, Addetia A, et al. Prospective mapping of viral mutations that
263 escape antibodies used to treat COVID-19. Science 2021.
- 264 18. Helleberg M, Niemann CU, Moestrup KS, et al. Persistent COVID-19 in an
265 Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy.
266 J Infect Dis 2020;222:1103-7.
- 267 19. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide
268 analysis in China. Lancet Oncol 2020;21:335-7.


269 20. Vardhana SA, Wolchok JD. The many faces of the anti-COVID immune response. J Exp
270 Med 2020;217.

271 21. Broers AE, van Der Holt R, van Esser JW, et al. Increased transplant-related morbidity
272 and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease
273 after allogeneic T-cell-depleted stem cell transplantation. Blood 2000;95:2240-5.

274 22. Okoye IS, Xu L, Walker J, Elahi S. The glucocorticoids prednisone and dexamethasone
275 differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune
276 checkpoint blockade. Cancer Immunol Immunother 2020;69:1423-36.

277


278



279

280 **Fig1. Clinical and genomic characterization of SARS-CoV-2 variations in an**
281 **immunocompromised patient. (A)**, Clinical timeline of events of the immunocompromised
282 patient. **(B)**, SARS-CoV-2 genotypes of the major haplotypes from the swab (swab-1) and
283 tracheal aspirate samples (TA-1, day 7; TA-2, day 21 and TA-3, day 27). **(C)**, The phylogenetic
284 clades of SARS-CoV-2 variants. The tree was generated using Nextclade
285 (clades.nextstrain.org). The nodes are highlighted by the Nextstrain clades. The clades
286 associated with E484K mutations are denoted by red arrows, while the B.1.369 genomes
287 described in this study are illustrated by a black arrow. **(D)**, The mutation frequency changes
288 among the swab and tracheal aspirate samples over time.

289



290

291 **Fig 2. Global distribution of S protein E484K mutation.** A maximum-likelihood phylogenetic
292 tree with the 4 patient sequences (B.1.369) and 1,983 selected SARS-CoV-2 genomes from the
293 GISAID database (date as 2/12/2021) is annotated using iTOL (www.itol.embl.de). The scale
294 represents 0.0001 nucleotide substitutions per site. The SARS-CoV-2 Pangolin lineage and
295 country are illustrated as two outer rings in different colors.

296

297

Table 1 Cycle-threshold values of SARS-CoV-2 samples

Sample	Ct for N2 target
Swab-1 (Day 0)	24.34
TA-1 (Day 7)	20.43
TA-2 (Day 21)	15.39
TA-3 (Day 27)	24.65
Swab-2 (Day 34)	37.14
Swab-3 (Day 41)	32.39

298

299